inflAmmatory maRkers in Blood and Thrombus Aspirated From Patients With acutE myocaRdial Infarction With St-segment elevAtion

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01757886

Acronym

ARTERIA

Enrollment

100

Registered

2012-12-31

Start date

2012-11-30

Completion date

2013-11-30

Last updated

2012-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Admitted With the Diagnosis of ST-elevation Acute Coronary Syndrome

Keywords

Myocardial infarction, Inflammation, Thrombus, Coronary angioplasty.

Brief summary

The prognostic value of inflammatory markers in acute coronary syndrome has been extensively demonstrated, however it is still unknown whether there is an association between circulating and local (thrombus) inflammatory molecules, and the subset of molecules that provide better prognostic information in patients with ST-elevation acute coronary syndrome.

Interventions

OTHERBiomarkers to analyze both intracoronary thrombi as blood

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* They include patients of both sexes, without limits of age, with a diagnosis of STEMI within 12 hours after the beginning of symptoms. ST-elevation myocardial infarction was defined in the presence of symptoms consistent, persistent elevation (\> 20 min) ST segment ≥ 1 mm in at least two contiguous leads or in the presence of left bundle branch block presumably new onset and cardiac troponin I elevation

Exclusion criteria

* Injury significant common core of left coronary artery (stenosis greater than or equal to 50% of the vessel lumen). * Pre-Fibrinolysis percutaneous coronary intervention. * Previous coronary bypass surgery. * Thyrotoxicosis. * Having an inflammatory systemic or local inflammatory process. * Malignant neoplasm. * Any disease that seriously compromise the prognosis and / or systemic inflammatory response generated. * No thrombotic material obtained in the thrombus or insufficient for performing biochemical determinations.

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is to find out whether there is an association between certain inflammatory markers in blood and intracoronary thrombus and whether these markers are associated with the composite of all-cause mortality	one year

Countries

Spain

Contacts

Primary ContactAlberto Dominguez-Rodriguez, MD, PhD

adrvdg@hotmail.com+34 922 679040

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026